ES2302402B1 - Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. - Google Patents
Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. Download PDFInfo
- Publication number
- ES2302402B1 ES2302402B1 ES200501468A ES200501468A ES2302402B1 ES 2302402 B1 ES2302402 B1 ES 2302402B1 ES 200501468 A ES200501468 A ES 200501468A ES 200501468 A ES200501468 A ES 200501468A ES 2302402 B1 ES2302402 B1 ES 2302402B1
- Authority
- ES
- Spain
- Prior art keywords
- alpha
- interferon
- cytokine
- family
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 123
- 102000006992 Interferon-alpha Human genes 0.000 title claims abstract description 123
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 title abstract description 12
- 229950000038 interferon alfa Drugs 0.000 title description 2
- 102000004127 Cytokines Human genes 0.000 claims abstract description 105
- 108090000695 Cytokines Proteins 0.000 claims abstract description 105
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 83
- 230000003612 virological effect Effects 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 86
- 102100028892 Cardiotrophin-1 Human genes 0.000 claims description 83
- 108010041776 cardiotrophin 1 Proteins 0.000 claims description 83
- 102000004140 Oncostatin M Human genes 0.000 claims description 27
- 108090000630 Oncostatin M Proteins 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 102000014150 Interferons Human genes 0.000 claims description 18
- 108010050904 Interferons Proteins 0.000 claims description 18
- 229940079322 interferon Drugs 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 15
- 108090000177 Interleukin-11 Proteins 0.000 claims description 11
- 102000003815 Interleukin-11 Human genes 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 108010002871 cardiotrophin-like cytokine Proteins 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 8
- 230000001766 physiological effect Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 208000005176 Hepatitis C Diseases 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 230000001886 ciliary effect Effects 0.000 claims description 5
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 4
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003900 neurotrophic factor Substances 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 61
- 238000000034 method Methods 0.000 abstract description 13
- 108020004414 DNA Proteins 0.000 abstract description 11
- 229940100601 interleukin-6 Drugs 0.000 abstract description 6
- 241000711549 Hepacivirus C Species 0.000 description 77
- 108010078049 Interferon alpha-2 Proteins 0.000 description 71
- 210000004027 cell Anatomy 0.000 description 68
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 37
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 37
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 35
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 35
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 34
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 34
- 230000000840 anti-viral effect Effects 0.000 description 27
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 21
- 230000004913 activation Effects 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 108010085238 Actins Proteins 0.000 description 11
- 241000710188 Encephalomyocarditis virus Species 0.000 description 10
- 208000036142 Viral infection Diseases 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 230000009385 viral infection Effects 0.000 description 10
- 102000007469 Actins Human genes 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 102000015696 Interleukins Human genes 0.000 description 6
- 108010063738 Interleukins Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 4
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 4
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 4
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 4
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 4
- 230000001120 cytoprotective effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 3
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 2
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 2
- 208000026375 Salivary gland disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108030002617 2'-5' oligoadenylate synthases Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 1
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 230000035986 JAK-STAT signaling Effects 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 108010000837 Janus Kinase 1 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710085061 Orsellinic acid synthase Proteins 0.000 description 1
- 101710110277 Orsellinic acid synthase armB Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- -1 STAT2 Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102000015774 TYK2 Kinase Human genes 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 101710085459 p48 protein Proteins 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 229940106366 pegintron Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2073—IL-11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5415—Leukaemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5431—IL-11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200501468A ES2302402B1 (es) | 2005-06-16 | 2005-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. |
| AU2006258966A AU2006258966B8 (en) | 2005-06-16 | 2006-06-16 | Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha |
| PCT/ES2006/000353 WO2006134195A2 (es) | 2005-06-16 | 2006-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa |
| CN2006800299002A CN101257918B (zh) | 2005-06-16 | 2006-06-16 | 来自白介素-6家族的细胞因子在用于与干扰素-α组合施用的组合物的制备中的用途 |
| EP06794028A EP1905447A4 (en) | 2005-06-16 | 2006-06-16 | USE OF A CYTOKIN OF THE INTERLEUKIN 6 FAMILY FOR THE PREPARATION OF A CONNECTION TO COMBINED DISPERSION WITH INTERFERON ALPHA |
| MX2007016060A MX2007016060A (es) | 2005-06-16 | 2006-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. |
| RU2008100307/15A RU2413529C2 (ru) | 2005-06-16 | 2006-06-16 | Применение цитокина из семейства интерлейкина-6 для получения композиции для комбинированного введения с интерфероном-альфа |
| US11/922,221 US7829077B2 (en) | 2005-06-16 | 2006-06-16 | Treatment of hepatitis C with compositions comprising oncostatin M and interferon alpha |
| BRPI0611988-3A BRPI0611988A2 (pt) | 2005-06-16 | 2006-06-16 | uso de pelo menos um citoquina da famìlia il-6 famìlia gp130, composição farmacêutica, kit farmacêutico e método para o tratamento de uma enfermidade viral |
| CA2612282A CA2612282C (en) | 2005-06-16 | 2006-06-16 | Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha |
| JP2008516350A JP5154412B2 (ja) | 2005-06-16 | 2006-06-16 | インターフェロンアルファとの組み合わせ投与のための組成物の調製における、インターロイキン６ファミリーサイトカインの使用 |
| US12/887,843 US20110027224A1 (en) | 2005-06-16 | 2010-09-22 | Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200501468A ES2302402B1 (es) | 2005-06-16 | 2005-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2302402A1 ES2302402A1 (es) | 2008-07-01 |
| ES2302402B1 true ES2302402B1 (es) | 2009-05-08 |
Family
ID=37532659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200501468A Expired - Fee Related ES2302402B1 (es) | 2005-06-16 | 2005-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7829077B2 (enExample) |
| EP (1) | EP1905447A4 (enExample) |
| JP (1) | JP5154412B2 (enExample) |
| CN (1) | CN101257918B (enExample) |
| AU (1) | AU2006258966B8 (enExample) |
| BR (1) | BRPI0611988A2 (enExample) |
| CA (1) | CA2612282C (enExample) |
| ES (1) | ES2302402B1 (enExample) |
| MX (1) | MX2007016060A (enExample) |
| RU (1) | RU2413529C2 (enExample) |
| WO (1) | WO2006134195A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA106591C2 (uk) * | 2008-07-23 | 2014-09-25 | Тамара Алєксандровна Віткалова | Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1 |
| JP2010059081A (ja) * | 2008-09-02 | 2010-03-18 | Okayama Univ | オンコスタチンｍを含有する抗ｈｃｖ剤およびその利用 |
| ES2342529B1 (es) | 2008-10-07 | 2011-05-11 | Proyecto De Biomedicina Cima, S.L. | Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas. |
| WO2011098644A2 (es) | 2010-02-09 | 2011-08-18 | Proyecto De Biomedicina Cima, S.L. | Composiciones para el tratamiento de enfermedades infecciosas y tumorales |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN110636854A (zh) | 2017-03-31 | 2019-12-31 | 阿卡尼斯生物技术F&E有限责任两合公司 | 非黑素瘤皮肤癌(nmsc)的预防和治疗 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN113197910B (zh) * | 2021-05-14 | 2022-09-23 | 苏州大学 | 一种基于阿司匹林及其代谢产物提高干扰素抗病毒活性的抗病毒药盒 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2006776A6 (es) * | 1986-07-08 | 1989-05-16 | Genetics Inst | Un procedimiento para producir una proteina il-6. |
| WO1997016204A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
| WO1999007409A1 (fr) * | 1997-08-04 | 1999-02-18 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral |
| WO2000037096A2 (en) * | 1998-12-22 | 2000-06-29 | Schering Corporation | Treatment of hepatitis c virus infections with interleukin-10 |
| ES2224246T3 (es) * | 1996-05-13 | 2005-03-01 | F. Hoffmann-La Roche Ag | Uso de composiciones sinergeticas de il-12 y inf-alfa para el tratamiento de enfermedadesinfecciosas. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284237B1 (en) | 1986-07-08 | 2001-09-04 | Steven C. Clark | Methods of treatment using IL-6 |
| US6348191B1 (en) | 1986-07-08 | 2002-02-19 | Genetics Institute, Inc. | Production and use of IL-6 |
| US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| WO1998012332A1 (en) * | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
| ES2200646B1 (es) * | 2001-09-21 | 2005-05-01 | Fundacion Para La Investigacion Medica Aplicada | Uso de la cardiotrofina en enfermedades hepaticas. |
| TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| RU2222345C2 (ru) * | 2002-01-21 | 2004-01-27 | Волчек Игорь Анатольевич | Фармацевтическая композиция цитокинового и иммуномодулирующего действия |
| US20050027110A1 (en) * | 2003-07-24 | 2005-02-03 | Michael Russell | Drug delivery in the nervous system |
-
2005
- 2005-06-16 ES ES200501468A patent/ES2302402B1/es not_active Expired - Fee Related
-
2006
- 2006-06-16 RU RU2008100307/15A patent/RU2413529C2/ru not_active IP Right Cessation
- 2006-06-16 JP JP2008516350A patent/JP5154412B2/ja not_active Expired - Fee Related
- 2006-06-16 BR BRPI0611988-3A patent/BRPI0611988A2/pt not_active IP Right Cessation
- 2006-06-16 AU AU2006258966A patent/AU2006258966B8/en not_active Ceased
- 2006-06-16 CA CA2612282A patent/CA2612282C/en not_active Expired - Fee Related
- 2006-06-16 CN CN2006800299002A patent/CN101257918B/zh not_active Expired - Fee Related
- 2006-06-16 US US11/922,221 patent/US7829077B2/en not_active Expired - Fee Related
- 2006-06-16 MX MX2007016060A patent/MX2007016060A/es active IP Right Grant
- 2006-06-16 WO PCT/ES2006/000353 patent/WO2006134195A2/es not_active Ceased
- 2006-06-16 EP EP06794028A patent/EP1905447A4/en not_active Withdrawn
-
2010
- 2010-09-22 US US12/887,843 patent/US20110027224A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2006776A6 (es) * | 1986-07-08 | 1989-05-16 | Genetics Inst | Un procedimiento para producir una proteina il-6. |
| WO1997016204A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
| ES2224246T3 (es) * | 1996-05-13 | 2005-03-01 | F. Hoffmann-La Roche Ag | Uso de composiciones sinergeticas de il-12 y inf-alfa para el tratamiento de enfermedadesinfecciosas. |
| WO1999007409A1 (fr) * | 1997-08-04 | 1999-02-18 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral |
| WO2000037096A2 (en) * | 1998-12-22 | 2000-06-29 | Schering Corporation | Treatment of hepatitis c virus infections with interleukin-10 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006134195A8 (es) | 2008-01-31 |
| AU2006258966B8 (en) | 2011-12-08 |
| JP5154412B2 (ja) | 2013-02-27 |
| RU2413529C2 (ru) | 2011-03-10 |
| US7829077B2 (en) | 2010-11-09 |
| WO2006134195A2 (es) | 2006-12-21 |
| EP1905447A2 (en) | 2008-04-02 |
| ES2302402A1 (es) | 2008-07-01 |
| CA2612282A1 (en) | 2006-12-21 |
| US20110027224A1 (en) | 2011-02-03 |
| CN101257918A (zh) | 2008-09-03 |
| AU2006258966B2 (en) | 2011-11-17 |
| CA2612282C (en) | 2014-03-25 |
| EP1905447A4 (en) | 2012-04-25 |
| CN101257918B (zh) | 2011-09-21 |
| BRPI0611988A2 (pt) | 2010-10-13 |
| WO2006134195A3 (es) | 2007-04-19 |
| RU2008100307A (ru) | 2009-07-27 |
| US20090130055A1 (en) | 2009-05-21 |
| AU2006258966A1 (en) | 2006-12-21 |
| MX2007016060A (es) | 2008-03-10 |
| JP2008546672A (ja) | 2008-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110027224A1 (en) | Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha | |
| Li et al. | Interferon-omega: Current status in clinical applications | |
| Gao et al. | STAT proteins–key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver | |
| KR101755058B1 (ko) | 특정 ｈｃｖ ｎｓ５ａ 억제제 및 ｈｃｖ ｎｓ３ 프로테아제 억제제의 조합물 | |
| JP4001379B2 (ja) | ウィルス感染を治療する薬剤の調製におけるインターフェロンのサブタイプの使用 | |
| Ma et al. | Antiviral effect of interferon lambda against West Nile virus | |
| Pardy et al. | Running interference: Interplay between Zika virus and the host interferon response | |
| JP2023517616A (ja) | 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤 | |
| CN108712905A (zh) | 抗肝肿瘤病毒剂 | |
| US20040034206A1 (en) | Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors | |
| Rau et al. | CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c‐Jun N terminal kinase activation independent from the interferon pathway | |
| Martínez-Espinoza et al. | Current landscape of IFN-λ: induction, inhibition, and potential clinical applications to treat respiratory viral infections | |
| US20090074721A1 (en) | Methods for treating viral infection with oral or injectibel drug solution | |
| JP5114401B2 (ja) | ウイルス性疾患の予防又は治療剤 | |
| Lake-Bakaar | Current and future therapy for chronic hepatitis C virus liver disease | |
| Lin et al. | [12] TELAPREVIR (VX-950) IS A POTENT INHIBITOR OF HCV NS3 PROTEASES DERIVED FROM GENOTYPE NON-1 HCV-INFECTED PATIENTS | |
| ES2381266T3 (es) | Terapias de combinación de L-FMAU para el tratamiento de la infección por el virus de la hepatitis B | |
| WO2005032576A1 (ja) | Ｃ型肝炎治療剤 | |
| Qamar et al. | Therapeutic Modalities for Sar s-Cov-2 (Covid-19): Current Status and Role of Protease Inhibitors to Block Viral Entry Into Host Cells. | |
| Castillo et al. | Myeloid Cell Reservoirs: Role in HIV-Host Interplay and Strategies for Myeloid Reservoir Elimination | |
| Tedaldi | New drug targets for HIV and hepatitis C virus coinfection | |
| Huang et al. | [13] IN VITRO EVALUATION OF COMBINATION TREATMENT OF ACH-806 WITH INTERFERON; VX-950 AND NM 107 | |
| Saadh et al. | Macrophage migration inhibitory factor (MIF): a Janus-faced cytokine in viral pathogenesis and host defense | |
| Nair et al. | Interferon Regulatory Factor-1 Protects from Fatal | |
| Cook | Host Determinants of Protection and Pathogenesis during Chikungunya Virus Infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20080701 Kind code of ref document: A1 |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20180809 |